Bioreactors play a key role in heart valve tissue engineering by mimicking physiological conditions, but clinical translation requires resolving critical early-stage issues.
Bioreactors aid in vitro heart valve tissue engineering; leaves open clinical translation and efficacy trials.
Bioreactors have great potential in the successful development of tissue‐engineered heart valve replacements, both at the research stage and in commercial platforms. Their ability to mimick the chemical and physiological conditions of the body has allowed researchers to study in vitro cellular responses, and this has helped in the fabrication of better and more efficient tissues in vivo . Use of different bioreactors, such as, rotating, dynamic flexure, cyclic stretch and pulsatile bioreactors, in tissue engineering of heart valves has been widely investigated. However, this research is still at its early stage, and many critical issues need to be resolved to make tissue engineered heart valves sufficiently reliable for clinical applications. In the following article, after a brief introduction to the structure and role of heart valves, the efforts of tissue engineers in designing heart valves using different bioreactors is described.
No takes yet. Share an insight, caveat, or question.
Amrollahi et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: